As real world evidence (RWE) becomes a more prevalent resource for confirming and expanding product benefit-risk profiles, non-randomized studies (NRS) are emerging as a valuable generator of real world data (RWD). Joan Largent – Senior Director, Epidemiology and Outcomes Research at IQVIA – discusses the findings of her recent study and how researchers can utilize assessment tools for their ability to accurately assess NRS validity.
Novartis AG said on Sept. 1 the company agreed on a deal with Britain’s healthcare service provider for use of the drugmaker’s new anti-cholesterol product Leqvio, after the country’s healthcare cost agency NICE approved the medicine.
Denmark’s Novo Nordisk is acquiring New Jersey-based Emisphere Technologies in a deal worth about $1.8 billion.
Novartis AG’s gene therapy Luxturna for blindness is recommended for use on England’s public health service, according to the country’s healthcare cost-effectiveness watchdog NICE.
Paul Ranson, of global law firm Morgan Lewis’ London Life Science’s Practice, examines how the UK Biopharma must now adapt to a changing landscape.
